We’re excited to announce our investment in Hilo, the blood pressure intelligence platform, founded by Mattia Bertschi y Josep Solà, that’s redefining how hypertension is monitored and managed globally. We participated in their $42 million Series B round alongside a fantastic group of investors, including Earlybird Health, Wellington Partners, naturalX Health Ventures, and others. With this round, we also join an outstanding group of earlier backers who have supported Hilo’s journey from the start, including Khosla Ventures, Redalpine, Molten Ventures, Translink Capital, and Verve Ventures.
This brings Hilo’s total funding to over $100 million, a testament to both the size of the problem they are addressing and the strength of their solution. This new momentum will accelerate the company’s mission to manage blood pressure on a global scale and expand its presence into new markets, including Spain.
Hypertension affects over 1.28 billion people worldwide and is a leading cause of premature death, strokes, and heart attacks. Yet, despite its prevalence and severity, the tools we use to monitor it haven’t evolved much in over a century.
Most people still rely on cuff-based devices, which are uncomfortable, intermittent, and don’t allow for continuous monitoring. This leads to poor adherence and suboptimal management of a condition that requires constant vigilance.
The market has seen incremental improvements (from invasive methods to cuff-based devices, to digital monitors) but none have fully solved the challenge of making blood pressure monitoring continuous, comfortable, and actionable.
Hilo has developed a cuffless solution that uses photoplethysmography (PPG) to passively capture blood pressure data from the wrist. Their proprietary algorithms, built on years of research at the Swiss Center for Electronics and Microtechnology (CSEM), translate these optical signals into accurate blood pressure readings.
The system is designed for continuous, passive monitoring, automatically recording data approximately once an hour when the user is still. This approach eliminates the inconvenience and discomfort of traditional cuffs, enabling people to seamlessly track their blood pressure trends over time and at nighttime. This is very relevant because higher nighttime blood pressure and a riser pattern of nocturnal blood pressure have been significantly associated with the risk of cardiovascular disease and heart failure.
Key differentiators:
Since its early commercialization in 2022, Hilo has seen robust growth. Their B2C sales dominate revenue through direct-to-consumer channels like their website and Amazon, while their B2B segment is steadily expanding.
At Kfund, we back founders who are tackling fundamental, high-impact problems with bold technological solutions. Hilo’s team is not only rethinking a century-old standard but doing so with a clear vision, robust technology, and strong early market validation.
Their work sits at the intersection of hardware, software, and health data, a combination we believe will be central to the next decade of healthcare innovation. As populations age and chronic conditions like hypertension become even more prevalent, solutions like Hilo’s will be critical in shifting healthcare from reactive to proactive.
We are thrilled to join Hilo on their mission to transform blood pressure management and, ultimately, improve the lives of millions around the world.
We’re excited to announce our investment in Hilo, the blood pressure intelligence platform, founded by Mattia Bertschi y Josep Solà, that’s redefining how hypertension is monitored and managed globally. We participated in their $42 million Series B round alongside a fantastic group of investors, including Earlybird Health, Wellington Partners, naturalX Health Ventures, and others. With this round, we also join an outstanding group of earlier backers who have supported Hilo’s journey from the start, including Khosla Ventures, Redalpine, Molten Ventures, Translink Capital, and Verve Ventures.
This brings Hilo’s total funding to over $100 million, a testament to both the size of the problem they are addressing and the strength of their solution. This new momentum will accelerate the company’s mission to manage blood pressure on a global scale and expand its presence into new markets, including Spain.
Hypertension affects over 1.28 billion people worldwide and is a leading cause of premature death, strokes, and heart attacks. Yet, despite its prevalence and severity, the tools we use to monitor it haven’t evolved much in over a century.
Most people still rely on cuff-based devices, which are uncomfortable, intermittent, and don’t allow for continuous monitoring. This leads to poor adherence and suboptimal management of a condition that requires constant vigilance.
The market has seen incremental improvements (from invasive methods to cuff-based devices, to digital monitors) but none have fully solved the challenge of making blood pressure monitoring continuous, comfortable, and actionable.
Hilo has developed a cuffless solution that uses photoplethysmography (PPG) to passively capture blood pressure data from the wrist. Their proprietary algorithms, built on years of research at the Swiss Center for Electronics and Microtechnology (CSEM), translate these optical signals into accurate blood pressure readings.
The system is designed for continuous, passive monitoring, automatically recording data approximately once an hour when the user is still. This approach eliminates the inconvenience and discomfort of traditional cuffs, enabling people to seamlessly track their blood pressure trends over time and at nighttime. This is very relevant because higher nighttime blood pressure and a riser pattern of nocturnal blood pressure have been significantly associated with the risk of cardiovascular disease and heart failure.
Key differentiators:
Since its early commercialization in 2022, Hilo has seen robust growth. Their B2C sales dominate revenue through direct-to-consumer channels like their website and Amazon, while their B2B segment is steadily expanding.
At Kfund, we back founders who are tackling fundamental, high-impact problems with bold technological solutions. Hilo’s team is not only rethinking a century-old standard but doing so with a clear vision, robust technology, and strong early market validation.
Their work sits at the intersection of hardware, software, and health data, a combination we believe will be central to the next decade of healthcare innovation. As populations age and chronic conditions like hypertension become even more prevalent, solutions like Hilo’s will be critical in shifting healthcare from reactive to proactive.
We are thrilled to join Hilo on their mission to transform blood pressure management and, ultimately, improve the lives of millions around the world.
